PRESERVE-1 Research Study Recruitment

[admin]

PRESERVE-1
Goal: For women diagnosed with preeclampsia between 23 and 30 weeks:
• Safely prolong pregnancy by delaying delivery
• Improve outcomes of baby

Who can participate?
• At least 16 years of age or older
• Singleton pregnancy
• 23 to 30 weeks pregnant with a recent diagnosis of preeclampsia or superimposed preeclampsia
• Requiring monitoring in a hospital setting

Study Locations:
The PRESERVE-1 study will include 120 women at over 20 locations in North America: https://www.clinicaltrials.gov/ct2/show ... ocs=Y#locn.

Birmingham, AL
Mobile, AL
Irvine, CA
New Haven, CT
Tampa, FL
Louisville, KY
New Orleans, LA
St. Louis, MO
New York, NY
Cincinnati, OH
Providence, RI
Chattanooga, TN
Houston, TX
Galveston, TX
Salt Lake City, UT

Study Overview:
PRESERVE-1 is a Phase 3 clinical study for women who are diagnosed with preeclampsia between 23-30 weeks of their pregnancy. This study will assess if antithrombin (Recombinant), a man-made version of a naturally occurring blood protein, can increase the time that your baby stays in the womb, decrease the problems that you may experience or improve the health and well-being of your baby.

What to Expect:
Participation in this study will involve gathering your medical history, physical exams, blood and urine collection, taking the study medication, and monitoring for side effects under observation by a physician. Some participants will receive the medication and some participants will receive a placebo, which is a saline solution without active ingredients. Your baby will also be followed after delivery.

Learn more:
http://www.PRESERVE-1.org
http://www.clinicaltrials.gov/ct2/show/NCT02059135